Project Grant R43HL172515
Award Date
9/20/24
Completion Date
9/19/25
Dollars Obligated
$296K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This $568,264 Project Grant award (R41HL178144) from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports SAFI Biotherapeutics Inc., a pre-clinical blood cell therapy company, in developing an intensified and scalable bioprocess to manufacture human red blood cells (RBCs) derived from induced pluripotent stem cells (iPSCs). The goal is to create a renewable source of designer RBCs with unique Rh antigen profiles to...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $693,423 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Baylor College of Medicine. The grant will fund the development and validation of a disposable microfluidic device capable of efficiently purifying platelets for pediatric and neonatal transfusions. The project aims to optimize the Controlled Incremental Filtration (CIF) technology to remove contaminants from platelet units while preserving...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports the "Preclinical Evaluation of a Peptide-Amphiphile Derived Toroidal Oxygen Carrier" research project. The $715,110 award, effective February 1, 2025, aims to design and optimize a blood substitute prototype (nano-RBC/nRBC) based on a deformable nanoparticle that is morphologically similar to red blood cells and incorporates high per-particle...
This federal Project Grant award of $445,708 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to define the role of platelet ABO(H) blood group antigens in hemostasis (bleeding) and thrombosis (blood clots). The overarching goal is to gain mechanistic insight into how platelet ABO blood type affects binding to von Willebrand factor, a key regulator of platelet function and blood clotting. The...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), aims to develop hemostatic red blood cells (T-RBCs) targeted to collagen and fibrin for the treatment of non-compressible hemorrhage. The project, funded under the Cardiovascular Diseases Research (CFDA 93.837) program, will focus on synthesizing the T-RBCs, testing their ability to enhance clot formation and stability in vitro, and conducting a pilot hemostasis...
This $225,600 project grant awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to engineer a lab-on-a-particle platform to measure platelet function. The project will synthesize peptide-functionalized hydrogel microparticles to serve as individual test sites for studying platelet adhesion, activation, aggregation, and contraction. The research will utilize immobilized and suspended particle assays to measure...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $693,262 to conduct an individual patient data meta-analysis (IPDMA) on the effects of liberal versus restrictive red blood cell transfusion thresholds in patients with cardiovascular disease, including those with myocardial infarction, pre-existing cardiovascular disease, and cardiac surgery. The primary aim is to estimate the...
The federal Project Grant award K99HL169746 for $172,800.00, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to uncover the impact of innate immunity on transfusion medicine immunobiology. The research aims to define the key factors regulating the production and clinical significance of naturally occurring anti-ABO(H) blood group antibodies. Using a preclinical mouse model, the project will...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $465,000 in funding to Bloodworks, a non-profit organization in Seattle, Washington. The grant supports research to investigate the mechanisms by which chronic inflammation disrupts autophagy and mitophagy processes in platelets and red blood cells of individuals with sickle cell disease. The research aims to elucidate how this leads to the accumulation of...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $275,739 project grant under the Cardiovascular Diseases Research (CFDA 93.837) program to WR Biotech, LLC, a small disadvantaged business. The grant supports research on a novel technique called Improved Synchronization Modulation Electric Field (I-SMEF) to protect donor hearts and improve transplanted heart graft function during cold storage prior to heart transplantation in mice. The I-SMEF technique aims to maintain...